GHRP-2 (Pralmorelin) Research: Mechanism, Pituitary Testing and What Studies Measured

What is GHRP-2?

What is GHRP-2? It is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂, carrying a C-terminal amide. Its International Nonproprietary Name is pralmorelin, and in the older literature it also appears as KP-102. Three of its six positions are non-standard: two D-amino acids and the bulky unnatural residue D-2-naphthylalanine, which replaces the D-tryptophan found at position 2 of GHRP-6.

Pharmacologically it is an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the ghrelin receptor — the same receptor engaged by GHRP-6, hexarelin, ipamorelin and the non-peptide MK-677, and a different receptor from the one the GHRH analogues act on. Everything below describes chemistry, receptor pharmacology and what investigators measured.

Discovery and origin in the literature

GHRP-2 came out of the same programme that produced GHRP-6. Bowers and colleagues had spent years on structure–activity work around the original hexapeptide, and the numbered series that resulted was an optimisation exercise: keep the pharmacophore, swap residues, measure releasing activity. GHRP-2 is the analogue in which the position-2 D-tryptophan is replaced by D-2-naphthylalanine, and it is reported in that literature as more potent than the parent. Bowers reviewed the whole programme in Cell Mol Life Sci in 1998 (PMID 9893708), and revisited it in 2001 under a title that captures the field’s central surprise — Unnatural growth hormone-releasing peptide begets natural ghrelin (J Clin Endocrinol Metab, PMID 11297568).

The receptor these compounds act at was cloned by Howard and colleagues in 1996 (Science, PMID 8688086), and its endogenous ligand, ghrelin, followed in 1999. That history belongs to the family as a whole and is told in full on the GHRP-6 page; it is not repeated here. What is specific to GHRP-2 is what happened next — of all the GHRPs, this is the one that ended up in clinics as a test agent rather than as a treatment.

Reference data

Identity facts from the public chemical record (PubChem CID 6918245) and standard catalogue data. Fields that could not be sourced are omitted rather than estimated.

The naphthylalanine at position 2 is the analytically useful landmark. It is larger and more hydrophobic than the tryptophan it replaces, which shifts retention on a reversed-phase column relative to GHRP-6 and hexarelin, and it drops the molecular mass by roughly 55 Da relative to GHRP-6 despite being the bulkier side chain — because the rest of the substitutions changed too. Molecule and analytical facts only; no reconstitution volume, concentration or route is given or implied.

Mechanisms researchers have examined

The GHRP-2 mechanism literature is unusually well resolved, because the diagnostic use forced investigators to establish exactly where and how the compound acts. Each point is what studies characterised:

• GHS-R1a agonism — GHRP-2 binds and activates the ghrelin receptor cloned by Howard et al. (1996), a Gq-coupled receptor expressed in pituitary and hypothalamus, signalling through phospholipase C and intracellular calcium.
• Action does not require an intact GHRH receptor — the sharpest mechanistic result in this literature. Gondo et al. (2001, J Clin Endocrinol Metab, PMID 11443201) studied eleven individuals with isolated growth hormone deficiency caused by a homozygous inactivating mutation of the GHRH-receptor gene, alongside normal controls. GHRP-2 still produced a measurable rise in serum growth hormone in the mutated group — far smaller than in controls, but present — and the authors concluded that an intact GHRH signalling system is not an absolute requirement for GHRP-2 to act on pituitary somatotrophs. Read carefully, that result also shows how much of the normal response depends on an intact GHRH arm.
• Corticotroph response — the test literature treats an ACTH rise as an expected part of the GHRP-2 test rather than as an anomaly. Suzuki et al. (2022) explicitly recommend measuring ACTH during the test. Gondo et al. (2001) measured ACTH, cortisol and prolactin and reported basal and post-GHRP-2 levels were similar between their groups. This is receptor pharmacology at the pituitary, described neutrally.
• Central appetite circuitry — Tschöp et al. (2002, Endocrinology, PMID 11796511) used GHRP-2 in mice lacking neuropeptide Y to probe which hypothalamic pathway carries the fat-mass effect, implicating agouti-related protein. This is a mechanism dissection in a knockout model, not a body-composition result in people.

Research findings by area

Pituitary-function testing

This is the application the evidence actually supports, and it is what makes GHRP-2 different from every other compound in this cluster. Suzuki et al. (2022, J Endocr Soc, PMID 35795807) describe the GHRP-2 test as widely used in the diagnosis of growth hormone deficiency, and set out to establish whether it is also informative about the adrenal axis in hypothalamic-pituitary disorder. In thirty-six patients they compared it against cosyntropin stimulation, corticotropin-releasing-hormone tests and insulin tolerance tests, and reported that the ACTH response during the GHRP-2 test discriminated usefully for secondary adrenal insufficiency. Their conclusion was a recommendation about test methodology: measure ACTH as well as growth hormone during the test.

Reported plainly, that is what a well-characterised secretagogue is genuinely good for — provoking a pituitary and reading the answer. It is a measurement application, and it is described here as one.

What happened over five days

The other study worth stating in detail is the one least likely to appear on a vendor page. Nijland et al. (1998, Eur J Endocrinol, PMID 9820615) gave nine healthy young men a daily subcutaneous injection of GHRP-2 for five days and sampled repeatedly on days 1, 3 and 5. Growth hormone continued to be released throughout — but analysis of variance showed statistically significant response attenuation across the five days, with peak concentrations and areas under the curve falling day on day. Mean serum IGF-1 did not increase over the treatment period. Osteocalcin, a different marker of growth-hormone activity in tissue, did rise significantly.

Those are the study’s own findings, reported neither as a success nor a failure beyond what the paper states. They are included because the disconnect between a maintained secretory response and an unmoved IGF-1 is exactly the kind of detail that separates a mechanism from an outcome — and because a five-day study is short, so it establishes what happened over five days and nothing more.

Research models and evidence status

The GHRP-2 evidence base splits cleanly. On the diagnostic side there is real, current, peer-reviewed clinical work in defined patient populations, because pituitary-function testing is a question the compound can actually answer. On the therapeutic side there is essentially nothing comparable: no phase-3 programme, no registered treatment indication, and no approved product for a treatment use.

What is not established

No controlled human trial establishes an effect of GHRP-2 on body composition, muscle, recovery, ageing or sleep. The five-day human study that exists reported an attenuating growth-hormone response and no IGF-1 rise, which is close to the opposite of what the compound is usually marketed on. The appetite and fat-mass work is in genetically modified mice and was designed to dissect a hypothalamic pathway, not to demonstrate an outcome. Long-term safety data in healthy people do not exist, and the corticotroph response documented in the test literature means this is not a growth-hormone-selective molecule; the member of the family characterised as selective is ipamorelin, on its own page.

On anti-doping status, reported as fact and not as a use case: growth-hormone secretagogues, the GHRP family included, appear under section S2 of the World Anti-Doping Agency Prohibited List and are prohibited at all times, in and out of competition.

GHRP-2 among the ghrelin-receptor agonists

Placed against its siblings by the honest differentiator — what each one does besides release growth hormone — GHRP-2 is the one with a diagnostic identity and a documented ACTH response that testing protocols deliberately exploit. GHRP-6 is the original and the least selective, with a rodent appetite and adiposity literature. Hexarelin carries a second receptor, CD36, and a cardiac literature that follows from it. Ipamorelin is the selective member. MK-677 is not a peptide at all. Across the receptor divide, sermorelin, CJC-1295 and tesamorelin act at the GHRH receptor instead — and the Gondo study above is the cleanest published demonstration that the two arms really are separate systems. Receptor-family context only; nothing here is a protocol, a stack or a recommendation.

How to verify this compound yourself

Identity and purity for a hexapeptide rest on two orthogonal methods, both reported on the per-batch Certificate of Analysis:

• HPLC purity — reversed-phase chromatography separates the target from synthesis-related impurities and reports purity as a percentage of the chromatogram. Diastereomeric impurities matter here in particular: three of six positions are D-configured, and a partially racemised batch can look chemically similar while being pharmacologically different.
• Mass-spec identity — the measured mass is checked against the expected ≈ 818 Da. Because the GHRP family members sit within a few tens of daltons of one another, mass-spec identity is the check that confirms which family member is actually in the vial — a purity percentage alone cannot establish that.
• Endotoxin and sterility — where tested, separate quality attributes reported in EU/mg or as a sterility result, independent of chemical purity.

See how to read a COA for what each line on a certificate means, how to verify peptide purity for how the two methods fit together, and the self-serve verify tool to check the exact batch on a vial in hand.

Research-grade sourcing and verification

For laboratory research use only. GHRP-2 is not held in stock; it is listed as available to order in the sourcing catalogue, with a typical lead time of two to three weeks and a quote on request. Material supplied ships with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation at the lot level. Sourcing and identity-assurance framing only — nothing here speaks to outcomes.

Frequently asked questions

Literature cited

1. Bowers CY. “Growth hormone-releasing peptide (GHRP).” Cell Mol Life Sci. 1998;54(12):1316–1329. PMID 9893708. pubmed.ncbi.nlm.nih.gov/9893708.
2. Bowers CY. “Unnatural growth hormone-releasing peptide begets natural ghrelin.” J Clin Endocrinol Metab. 2001;86(4):1464–1469. PMID 11297568. pubmed.ncbi.nlm.nih.gov/11297568.
3. Howard AD, Feighner SD, Cully DF, et al. “A receptor in pituitary and hypothalamus that functions in growth hormone release.” Science. 1996;273(5277):974–977. PMID 8688086. pubmed.ncbi.nlm.nih.gov/8688086.
4. Gondo RG, Aguiar-Oliveira MH, Hayashida CY, et al. “Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor.” J Clin Endocrinol Metab. 2001;86(7):3279–3283. PMID 11443201. pubmed.ncbi.nlm.nih.gov/11443201.
5. Nijland EA, Strasburger CJ, Popp-Snijders C, van der Wal PS, van der Veen EA. “A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men.” Eur J Endocrinol. 1998;139(4):395–401. PMID 9820615. pubmed.ncbi.nlm.nih.gov/9820615.
6. Suzuki S, Ruike Y, Ishiwata K, et al. “Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder.” J Endocr Soc. 2022;6(8):bvac088. PMID 35795807. pubmed.ncbi.nlm.nih.gov/35795807.
7. Tschöp M, Statnick MA, Suter TM, Heiman ML. “GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein.” Endocrinology. 2002;143(2):558–568. PMID 11796511. pubmed.ncbi.nlm.nih.gov/11796511.
8. Müller TD, Nogueiras R, Andermann ML, et al. “Ghrelin.” Mol Metab. 2015;4(6):437–460. PMID 26042199. pubmed.ncbi.nlm.nih.gov/26042199.
9. National Center for Biotechnology Information. “PubChem Compound Summary for CID 6918245, Pralmorelin.” pubchem.ncbi.nlm.nih.gov/compound/6918245 (formula, mass, CAS 158861-67-7).
10. World Anti-Doping Agency. “The Prohibited List” — section S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org/en/prohibited-list.